Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has Exact Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EXAS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: EXAS's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: EXAS underperformed the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 48.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Exact Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 months ago | Simply Wall StThe Exact Sciences (NASDAQ:EXAS) Share Price Is Up 978% And Shareholders Are Delighted
7 months ago | Simply Wall StHere's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
9 months ago | Simply Wall StCan You Imagine How Jubilant Exact Sciences' (NASDAQ:EXAS) Shareholders Feel About Its 296% Share Price Gain?
Is Exact Sciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXAS ($96.11) is trading below our estimate of fair value ($102.34)
Significantly Below Fair Value: EXAS is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: EXAS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: EXAS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXAS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXAS is overvalued based on its PB Ratio (4.5x) compared to the US Biotechs industry average (3.3x).
How is Exact Sciences forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EXAS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EXAS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EXAS's revenue (16.8% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: EXAS's revenue (16.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXAS is forecast to be unprofitable in 3 years.
How has Exact Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXAS is currently unprofitable.
Growing Profit Margin: EXAS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EXAS is unprofitable, and losses have increased over the past 5 years at a rate of 31.8% per year.
Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.5%).
Return on Equity
High ROE: EXAS has a negative Return on Equity (-20.42%), as it is currently unprofitable.
How is Exact Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: EXAS's short term assets ($1.8B) exceed its short term liabilities ($628.9M).
Long Term Liabilities: EXAS's short term assets ($1.8B) do not cover its long term liabilities ($2.5B).
Debt to Equity History and Analysis
Debt Level: EXAS's debt to equity ratio (60.3%) is considered high.
Reducing Debt: EXAS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable EXAS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: EXAS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.1% per year.
What is Exact Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EXAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EXAS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXAS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXAS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EXAS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Conroy (54 yo)
Mr. Kevin T. Conroy serves as Director of Adaptive Biotechnologies Corporation since April 2019. Mr. Conroy has been the Chief Executive Officer and President at Exact Sciences Corporation since April 2, 2...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD18.72M) is above average for companies of similar size in the US market ($USD11.16M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
Experienced Management: EXAS's management team is considered experienced (2.8 years average tenure).
Experienced Board: EXAS's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.
Exact Sciences Corporation's company bio, employee growth, exchange listings and data sources
- Name: Exact Sciences Corporation
- Ticker: EXAS
- Exchange: NasdaqCM
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.488b
- Shares outstanding: 171.55m
- Website: https://www.exactsciences.com
Number of Employees
- Exact Sciences Corporation
- 5505 Endeavor Lane
- United States
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to de...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/12 22:49|
|End of Day Share Price||2021/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.